**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**





**FORM
      10-Q**





x
            QUARTERLY
                REPORT PURSUANT TO SECTION 13 OR 15(d)OF
                THE SECURITIES EXCHANGE ACT OF 1934For
                the quarterly period endedMarch
                31, 2008o
            TRANSITION
                REPORT PURSUANT TO SECTION 13 OR 15(d)OF
                THE SECURITIES EXCHANGE ACT OF 1934For
                the transition period from _____________ to _____________


Commission
      File Number 0-28674





CADUS
      CORPORATION





(Exact
      Name of Registrant as Specified on its Charter)








Delaware
            
            13-3660391(State
                of Other Jurisdiction of Incorporation or Organization)
            
            (I.R.S.
                Employer Identification No.)767
                Fifth Avenue, New York, New York
            
            10153(Address
                of Principal Executive Offices)
            
            (Zip
                Code)Registrant’s
                Telephone Number, Including Area Code
            
            (212)
                702-4315




Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be
      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
      the
      preceding 12 months (or for such shorter period that the registrant was required
      to file such reports), and (2) has been subject to such filing requirements
      for
      the past 90 days.




Yes
                x
            No
                o





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, a non-accelerated filer, or a smaller reporting company.
      See
      definition of “large accelerated filer,” “accelerated filer” and “smaller
      reporting company” in Rule 12-b-2 of the Exchange Act). (Check
      one):





Large
                accelerated filer o
            Accelerated
                filer oNon-accelerated
                filer o
            Smaller
                reporting company x(Do
                not check if a smaller reporting company)


Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12-b-2 of the Exchange Act).


Yes
                o
            No
                x





The
      number of shares of registrant’s common stock, $0.01 par value, outstanding as
      of April 30, 2008 was 13,144,040.





**CADUS
      CORPORATION**





**INDEX**


Page
                No.SPECIAL
                NOTE REGARDING FORWARD LOOKING STATEMENTS
            3PART
                I - CONDENSED CONSOLIDATED FINANCIAL INFORMATIONItem
                1.Condensed
                Consolidated Financial StatementsCondensed
                Consolidated Balance Sheets - March 31, 2008 (unaudited) and December
                31,
                2007 (audited)
            4Condensed
                Consolidated Statements of Operations - Three Months Ended March
                31, 2008
                and 2007 (unaudited)
            5Condensed
                Consolidated Statements of Cash Flows - Three Months Ended March
                31, 2008
                and 2007 (unaudited)
            6Notes
                to Condensed Consolidated Financial Statements (unaudited)
            7 -
                9Item
                2.Management’s
                Discussion and Analysis of Financial Condition and Results of
                Operations
            10
                - 11Item
                3.Quantitative
                and Qualitative Disclosures About Market Risk
            11Item
                4.Controls
                and Procedures
            11PART
                II - OTHER INFORMATIONItem
                1.Legal
                Proceedings
            11Item
                1A. Risk Factors
            12Item
                2.Unregistered
                Sales of Equity Securities and Use of Proceeds
            12Item
                3.Defaults
                Upon Senior Securities
            12Item
                4.Submission
                of Matters to a Vote of Security Holders
            12Item
                5.Other
                Information
            12Item
                6.Exhibits
            12SIGNATURES
            13EXHIBIT
                INDEX
            14










**SPECIAL
      NOTE REGARDING FORWARD LOOKING STATEMENTS**





Certain
      statements in this Quarterly Report on Form 10-Q constitute “forward-looking
      statements” within the meaning of Section 27A of the Securities Act of 1933 and
      Section 21E of the Securities Exchange Act of 1934, as amended. All statements
      other than statements of historical fact are “forward-looking statements” for
      purposes of federal and state securities laws, including any projections or
      expectations of earnings, revenue, financial performance, liquidity and capital
      resources or other financial items; any statement of our plans, strategies
      and
      objectives for our future operations; any statements regarding future economic
      conditions or performance; any statements of belief; and any statements of
      assumption underlying any of the foregoing. Forward-looking statements may
      include the words “may,” “will,” “should,” “could,” “would,” “predicts,”
“potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates” and other similar words. Although the Company believes
      that the expectations reflected in our forward-looking statements are
      reasonable, such forward-looking statements involve known and unknown risks,
      uncertainties, and other factors which may cause the actual results,
      performance, or achievements of the Company to be materially different from
      any
      future results, performance or achievements expressed or implied by such
      forward-looking statements. Factors that could cause or contribute to such
      differences include, but are not limited to, risks and uncertainties relating
      to
      the Company's ability to license its technologies to third parties, the
      Company's inability to acquire and operate other companies, the Company's
      capital needs and uncertainty of future funding, the Company's history of
      operating losses, the unpredictability of patent protection, risk of
      obsolescence of the Company's technologies, as well as other risks and
      uncertainties discussed in the Company’s annual report on Form 10-K for the year
      ended December 31, 2007. The forward-looking statements made in this Quarterly
      Report on Form 10-Q are made only as of the date hereof and the Company does
      not
      have or undertake any obligation to publicly update any forward-looking
      statements to reflect subsequent events or circumstances unless otherwise
      required by law.





3


ITEM
                  1.
              **CONDENSED
                  CONSOLIDATED FINANCIAL
                  STATEMENTS**


**CADUS
      CORPORATION**


**Condensed
      Consolidated Balance Sheets**





**ASSETS**March
                31,
              2008
            
            December
                31, 2007(Unaudited)
            
            (Audited)Current
                assets:Cash
                and cash equivalents
            
            $
            10,280,130
            
            $
            2,444,376Short
                term investments
            
            
            14,953,960
            
            
            22,960,545Interest
                receivable
            
            
            46,186
            
            
            102,518Prepaid
                and other current assets
            
            
            126,150
            
            
            1,150Total
                current assets
            
            
            25,406,426
            
            
            25,508,589Investment
                in other ventures
            
            
            189,066
            
            
            186,790Patents,
                net
            
            
            529,226
            
            
            550,834Total
                assets
            
            $
            26,124,718
            
            $
            26,246,213**LIABILITIES
                AND STOCKHOLDERS’ EQUITY**Current
                liabilities:Accrued
                expenses and other current liabilities
            
            $
            108,853
            
            $
            22,352Total
                current liabilities
            
            
            108,853
            
            
            22,352CommitmentsStockholders’
                equity:Common
                stock
            
            
            132,857
            
            
            132,857Additional
                paid-in capital
            
            
            59,847,149
            
            
            59,847,149Accumulated
                deficit
            
            
            (
                33,664,066
            )
            
            (
                33,456,070
            )Treasury
                stock
            
            
            (
                300,075
            )
            
            (
                300,075
            )Total
                stockholders’ equity
            
            
            26,015,865
            
            
            26,223,861Total
                liabilities and stockholder’s equity
            
            $
            26,124,718
            
            $
            26,246,213


See
      accompanying notes to condensed consolidated financial statements.





4





**CADUS
      CORPORATION**


**Condensed
      Consolidated Statements of Operations**





Three
                Months Ended
              March
                31,2008
            
            2007(Unaudited)
            
            (Unaudited)License
                and maintenance fees
            
            $
            100,000
            
            $
            100,000Total
                revenues
            
            
            100,000
            
            
            100,000Costs
                and expenses:General
                and administrative expenses
            
            
            245,276
            
            
            292,483Amortization
                of patent costs
            
            
            21,608
            
            
            21,608(Income)
                from equity in other ventures
            
            
            (
                2,276
            )
            
            (
                3,221
            )Total
                costs and expenses
            
            
            264,608
            
            
            310,870Operating
                loss
            
            
            (
                164,608
            )
            
            (
                210,870
            )Other
                income:Interest
                income
            
            
            236,518
            
            
            320,647Loss
                on write down of marketable securities
            
            
            --
            
            
            (
                668,246
            )Investment
                reduction to net asset value
            
            
            (
                279,906
            )
            
            --Loss
                before provision for income taxes
            
            
            (
                207,996
            )
            
            (
                558,469
            )Provision
                for income taxes
            
            
            --
            
            
            --Net
                loss
            
            
            ($
                207,996
            )
            
            ($
                558,469
            )Basic
                and diluted (loss) per weighted average share of common stock
                outstanding
            
            
            ($
                0.02
            )
            
            ($
                0.04
            )Weighted
                average shares of common stock outstanding –
                basic and
                diluted
            
            
            13,144,040
            
            
            13,144,040




See
      accompanying notes to condensed consolidated financial
      statements.


5


**CADUS
      CORPORATION**


**Condensed
      Consolidated Statements of Cash Flows**





Three
                Months Ended
              March
                31,2008
            
            2007(Unaudited)
            
            (Unaudited)Cash
                flows from operating activities:Net
                (loss)
            
            
            ($
                207,996
            )
            
            ($
                558,469
            )Adjustments
                to reconcile net (loss) to net cash provided by operating
                activities:Amortization
                of patent costs
            
            
            21,608
            
            
            21,608(Income)
                from equity in other ventures
            
            
            (
                2,276
            )
            
            (
                3,221
            )Loss
                on sale of marketable securities
            
            
            --
            
            
            668,246Investment
                reduction to net asset value
            
            
            279,906
            
            
            --Changes
                in assets and liabilities:(Increase)
                in prepaid and other current assets
            
            
            (
                68,668
            )
            
            (
                16,200
            )Increase
                in accrued expenses and other current liabilities
            
            
            86,501
            
            
            85,885Net
                cash provided by operating activities
            
            
            109,075
            
            
            197,849Cash
                flows provided by investing activities:Proceeds
                from redemption of investment
            
            
            7,726,679
            
            
            --Net
                cash provided by investing activities
            
            
            7,726,679
            
            
            --Net
                increase in cash and cash equivalents
            
            
            7,835,754
            
            
            197,849Cash
                and cash equivalents –beginning
                of period
            
            
            2,444,376
            
            
            24,602,202Cash
                and cash equivalents –end
                of
                period
            
            $
            10,280,130
            
            $
            24,800,051


See
        accompanying notes to condensed consolidated financial statements.


6


**CADUS
        CORPORATION**
 **Notes
        to Condensed Consolidated Financial Statements**




Note
      -
      1  **Organization
      and Basis of Preparation**





The
      information presented as of March 31, 2008 and for the three-month period then
      ended, is unaudited, but includes all adjustments (consisting only of normal
      recurring accruals) that the Company's management believes to be necessary
      for
      the fair presentation of results for the periods presented. Certain information
      and footnote disclosures normally included in financial statements prepared
      in
      accordance with accounting principles generally accepted in the United States
      of
      America have been omitted pursuant to the requirements of the Securities and
      Exchange Commission, although the Company believes that the disclosures included
      in these financial statements are adequate to make the information not
      misleading. The December 31, 2007 condensed consolidated balance sheet was
      derived from audited consolidated financial statements. These financial
      statements should be read in conjunction with the Company's annual report on
      Form 10-K for the year ended December 31, 2007.





The
      consolidated financial statements include the accounts of the Company and its
      wholly owned subsidiary, Cadus Technologies, Inc. All intercompany balances
      and
      transactions have been eliminated in consolidation.




The
      results of operations for the three-month period ended March 31, 2008 are not
      necessarily indicative of the results to be expected for the year ending
      December 31, 2008.





Note
      -
      2  **Net
      (Loss) Per Share**




For
      the
      three-month periods ended March 31, 2008 and 2007 basic net (loss) per share
      is
      computed by dividing the net (loss) by the weighted average number of common
      shares outstanding. Diluted earnings per share for the three months ended March
      31, 2008 and 2007 was the same as basic earnings per share as all of the
      Company’s outstanding options’ and warrants’ exercise prices were greater than
      the average market price of the common shares. For this reason, for the three
      months ended March 31, 2008 and 2007, respectively, 0 and 2,500 options and
      warrants were excluded from the calculation of diluted earnings per
      share.





Note
      -
      3  **Licensing
      Agreements**





In
      February 2000, Cadus licensed to OSI Pharmaceuticals, Inc. (“OSI”), on a
      non-exclusive basis, its yeast-based drug discovery technologies, including
      various reagents and its library of over 30,000 yeast strains, and its
      bioinformatics software. OSI paid to Cadus a license fee of $100,000 and an
      access fee of $600,000 and in December 2000 a supplemental license fee of
      $250,000. OSI is also obligated to pay an annual maintenance fee of $100,000
      until the earlier of 2010 or the termination of the license. OSI may terminate
      the license at any time on 30 days prior written notice. During the three-month
      period ended March 31, 2008 and 2007, the Company recognized $100,000 of license
      revenue related to this agreement.





Note
      -
      4  **Accounting
      for Impairment of Long-Lived Assets**





Statement
      of Financial Accounting Standards No. 144, “ *Accounting
      for the Impairment or Disposal of Long-Lived Assets* ”
(“SFAS
      144"), addresses financial accounting and reporting for the impairment or
      disposal of long-lived assets. The Company’s long-lived assets (principally
      capitalized patent costs) are required to be measured at the lower of carrying
      amount or fair value, less cost to sell, whether reported in continuing
      operations or discontinued operations. Intangibles with determinable lives
      and
      other long-lived assets are reviewed for impairment whenever events or changes
      in circumstances indicate that the carrying value of an asset may not be
      recoverable. The Company’s judgments regarding the existence of impairment
      indicators are based on historical and projected future operating results,
      changes in the Company’s overall business strategy, and market and economic
      trends. In the future, events could cause the Company to conclude that
      impairment indicators exist and that certain intangibles with determinable
      lives
      and other long-lived assets are impaired which may result in an adverse impact
      on the Company’s financial condition and results of operations. The provisions
      of SFAS No. 144 did not have an impact on the Company’s financial statements as
      of and for the three months ended March 31, 2008.





7





**CADUS
      CORPORATION**


**Notes
      to Condensed Consolidated Financial Statements**




Note
      -
      5  **Short
      Term Investments**





The
      company invested its excess cash with Bank of America in its Columbia Strategic
      Cash Portfolio (the “Fund”), which maintained a stable unit price of $1.00 per
      unit. The units were redeemable in cash on the same day requested and were
      classified by the Company as cash equivalents.





On
      December 10, 2007, the Fund notified the Company that conditions in the short
      term credit markets had created a broad based perception of risk in non-sub
      prime asset-backed securities causing illiquidity across the market which led
      to
      extreme pricing pressure in those securities. The Fund also notified the Company
      that it is primarily invested in such securities, that it will begin an orderly
      liquidation of such securities, that unit holders would no longer be able to
      redeem their units in the Fund and that the Fund would redeem its units as
      it
      liquidated its investments. The Fund also began to value its securities based
      on
      market value rather than amortized value for the purposes of determining net
      asset value per unit. The Fund has continued to pay interest monthly. From
      January 1, 2008 through March 31, 2008, the Fund redeemed 7,838,675 units in
      the
      Fund for $7,726,679, which redemption was $111,996 in the aggregate less than
      the original $7,838,675 cost of such units. At the close of business on March
      31, 2008 the Company still owned 15,414,864 units in the Fund which had an
      aggregate value at such time of $14,953,960. The Fund has advised the Company
      that it anticipates that the balance, or most of the balance, of the Company’s
      investment in the Fund will be redeemed by December 31, 2008. However, there
      can
      be no assurance as to when further redemptions will take place or as to the
      net
      asset value at which the balance of the Company’s investment in the Fund will be
      redeemed.





Note
      -
      6  **Recently
      Issued Accounting Pronouncements**





In
      June
      2006, the FASB issued Interpretation No. 48, “ *Accounting
      for Uncertainty in Income Taxes - an interpretation of FASB Statement No.
      109* ”,
      which
      provides guidance for the financial statement recognition and measurement of
      a
      tax position taken or expected to be taken in a tax return as well as subsequent
      changes in a tax position, calculation of interest and penalties, accounting
      in
      interim periods, disclosure, and transition. The Interpretation became effective
      for the Company on January 1, 2007 and has not had a significant impact on
      the
      Company’s financial position or results of operations.





8





**CADUS
      CORPORATION**


**Notes
      to Condensed Consolidated Financial Statements**






In
      September 2006, the FASB issued SFAS No. 157, “*Fair
      Value Measures*”,
      which
      defines fair value, establishes a framework for measuring fair value under
      generally accepted accounting principles, and expands disclosures about fair
      value measures. This Statement applies under other accounting pronouncements
      that require or permit fair value measurements; it does not require any new
      fair
      value measures. SFAS No. 157 became effective for the Company on January 1,
      2008
      and did not have a significant impact on the Company’s financial position or
      results of operations.





In
      February 2007, the FASB issued SFAS No. 159, *“The
      Fair Value Option for Financial Assets and Financial Liabilities”* (“SFAS
      159”), which permits certain financial assets and financial liabilities to be
      measured at fair value, using an instrument-by-instrument election. The initial
      effect of adopting SFAS 159 must be accounted for as a cumulative-effect
      adjustment to opening retained earnings for the fiscal year in which we apply
      SFAS 159. Retrospective application of SFAS 159 to fiscal years preceding the
      effective date is not permitted. SFAS 159 has no effect on the Company’s
      financial statements.





In
      December 2007, the FASB issued SFAS No. 141(R), *“Business
      Combinations”* (“SFAS
      141(R)”). SFAS 141(R) expands the definition of transactions and events that
      qualify as business combinations; requires that the acquired assets and
      liabilities, including contingencies, be recorded at the fair value determined
      on the acquisition date and changes thereafter reflected in revenue, not
      goodwill; changes the recognition timing for restructuring costs; and requires
      acquisition costs to be expensed as incurred. Adoption of SFAS 141(R) is
      required for combinations after December 15, 2008. Early adoption and
      retroactive application of SFAS 141(R) to fiscal years preceding the effective
      date are not permitted. The adoption of SFAS 141(R) may have an effect on the
      Company's financial statements.





In
      December 2007, the FASB issued SFAS No. 160 *,
      “Noncontrolling Interest in Consolidated Financial Statements”* (“SFAS
      160”). SFAS 160 re-characterizes minority interests in consolidated subsidiaries
      as non-controlling interests and requires the classification of minority
      interests as a component of equity. Under SFAS 160, a change in control will
      be
      measured at fair value, with any gain or loss recognized in earnings. The
      effective date for SFAS 160 is for annual periods beginning on or after December
      15, 2008. Early adoption and retroactive application of SFAS 160 is for annual
      periods beginning on or after December 15, 2008. Early adoption and retroactive
      application of SFAS 160 to fiscal years preceding the effective date are not
      permitted. We are evaluating the impact of adoption on our consolidated
      financial statements.




9


ITEM
                2.
            **MANAGEMENT'S
                DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
                OPERATIONS**





**Overview**





The
      Company was incorporated in 1992 and until July 30, 1999, devoted substantially
      all of its resources to the development and application of novel yeast-based
      and
      other drug discovery technologies. On July 30, 1999, the Company sold its drug
      discovery assets and ceased its internal drug discovery operations and research
      efforts for collaborative partners.





At
      March
      31, 2008, the Company had an accumulated deficit of approximately $33.7 million.
      The Company’s losses have resulted principally from costs incurred in connection
      with its research and development activities and from general and administrative
      costs associated with the Company’s operations. These costs have exceeded the
      Company’s revenues and interest income. As a result of the sale of its drug
      discovery assets and the cessation of its internal drug discovery operations
      and
      research efforts for collaborative partners, the Company ceased to have research
      funding revenues and substantially reduced its operating expenses. The Company
      expects to generate revenues in the future only if it is able to license its
      technologies.





**Results
      of Operations**





*Three
      Months Ended March 31, 2008 and March 31, 2007*





*Revenues*





Revenues
      for the three months ended March 31, 2008 and 2007 were $100,000, which is
      the
      annual maintenance fee from OSI.





*Costs
      and Expenses*





General
      and administrative expenses decreased to $245,276 for the three months ended
      March 31, 2008 from $292,483 for the same period in 2007. Patent costs decreased
      by $32,858, accounting and legal expenses decreased by $22,752, consulting
      costs
      increased by $8,265 due to the use of an internal control consultant to conform
      with Section 404 of the Sarbanes-Oxley Act. There were net other increases
      of
      $138.





For
      the
      three months ended March 31, 2008 the Company recognized income of $2,276 in
      its
      investment in Laurel Partners Limited Partnership. The income for the same
      period in 2007 was $3,221.





*Interest
      Income*





Interest
      income for the three months ended March 31, 2008 was $236,518 compared to
      interest income of $320,647 for the same period in 2007. This decrease is
      attributable primarily to lower interest rates earned on invested
      funds.





*Net
      (Loss)*





Net
      loss
      for the three months ended March 31, 2008 was $207,996 compared to a net loss
      of
      $558,469 for the same period in 2007. The decrease in net loss can be attributed
      to a decrease in general and administrative expenses of $47,207 and the
      2007 loss on write down of marketable securities of $668,246, offset by the
      a
      $279,906 reduction in short term investment to net asset value in 2008, and
      decreases in interest income and income from equity in other ventures of $84,129
      and $945, respectively.





10


*Liquidity
      and Capital Resources*





At
      March
      31, 2008 the Company held cash and cash equivalents of $10.3 million and
      short-term investments of $15 million. The Company's working capital at March
      31, 2008 was $25.3 million.





The
      Company believes that its existing capital resources, together with interest
      income, will be sufficient to support its operations through the end of 2009.
      This forecast of the period of time through which the Company's financial
      resources will be adequate to support its operations is a forward-looking
      statement that may not prove accurate and, as such, actual results may vary.
      The
      Company's capital requirements may vary as a result of a number of factors,
      including the transactions, if any, arising from the Company's efforts to
      acquire or invest in companies and income-producing assets and the expenses
      of
      pursuing such transactions.





Item
                3.
            **QUANTITATIVE
                AND QUALITATIVE DISCLOSURES ABOUT MARKET
                RISK**





The
      Company's earnings and cash flows are subject to fluctuations due to changes
      in
      interest rates primarily from its investment of available cash balances in
      money
      market funds with portfolios of investment grade corporate and U.S. government
      securities. The Company does not believe it is materially exposed to changes
      in
      interest rates. Under its current policies the Company does not use interest
      rate derivative instruments to manage exposure to interest rate
      changes.





Item
      4.  **CONTROLS
      AND PROCEDURES**





Based
      on
      the evaluation of the Company’s disclosure controls and procedures conducted as
      of the end of the period covered by this report on Form 10-Q, the Company’s
      President and Chief Executive Officer, who also performs the functions of a
      principal financial officer, concluded that the Company’s disclosure controls
      and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under
      the Securities Exchange Act of 1934) are effective. In addition, there has
      been
      no change in the Company’s internal control over financial reporting (as defined
      in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934)
      that
      occurred during the period covered by this report on Form 10-Q that has
      materially affected, or is reasonably likely to materially affect, the Company’s
      internal control over financial reporting. It should be noted that any system
      of
      controls, however well designed and operated, can provide only reasonable
      assurance, and not absolute assurance, that the objectives of the system are
      met. In addition, the design of any control system is based in part upon certain
      assumptions about the likelihood of future events. Because of these and other
      inherent limitations of control systems, there can be no assurance that any
      design will succeed in achieving its stated goals under all potential future
      conditions, regardless of how remote.




**PART
      II - OTHER INFORMATION**





ITEM
      1.  LEGAL
      PROCEEDINGS .





None.





11


ITEM
      1A.  RISK
      FACTORS .





There
      were no material changes from the risk factors previously disclosed in our
      Annual Report on Form 10-K for the period ended December 31, 2007 as filed
      with
      the Securities and Exchange Commission on March 31, 2008.





ITEM
      2.  UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.





None.





ITEM
      3.  DEFAULTS
      UPON SENIOR SECURITIES.





None.





ITEM
      4.  SUBMISSION
      OF MATTERS TO A VOTE OF SECURITY HOLDERS.





None.





ITEM
      5.  OTHER
      INFORMATION .





None.





ITEM
      6.  EXHIBITS .





The
      Exhibits listed in the Exhibit Index are included in this quarterly report
      on
      Form 10-Q.




12





**SIGNATURES**





Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned thereunto
      duly authorized.


**CADUS
                CORPORATION**
              **(Registrant)**Dated:May
              15, 2008
            By:
            /s/
              David BlitzDavid
                BlitzPresident
                and Chief Executive Officer (Authorized Officer and Principal Financial
                Officer)




13


**EXHIBIT
      INDEX**





The
                following exhibits are filed as part of this Quarterly Report on
                Form
                10-Q:Exhibit
                No.
            Description31
            Certifications32
            Certification
                Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section
                906 of
                the Sarbanes-Oxley Act of 2002




14